Last reviewed · How we verify
Brompheniramine + pseudoephedrine
Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while pseudoephedrine stimulates alpha-adrenergic receptors to constrict nasal blood vessels and relieve congestion.
Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while pseudoephedrine stimulates alpha-adrenergic receptors to constrict nasal blood vessels and relieve congestion. Used for Allergic rhinitis with nasal congestion, Urticaria and pruritus associated with allergies, Upper respiratory allergy symptoms.
At a glance
| Generic name | Brompheniramine + pseudoephedrine |
|---|---|
| Also known as | Group 2 |
| Sponsor | Ache Laboratorios Farmaceuticos S.A. |
| Drug class | Antihistamine + decongestant combination |
| Target | H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Brompheniramine is a first-generation antihistamine that crosses the blood-brain barrier and competitively antagonizes H1 receptors, reducing itching, sneezing, and urticaria associated with allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-1 adrenergic agonist on nasal mucosa vasculature, causing vasoconstriction and reducing nasal congestion. Together, they provide complementary symptomatic relief for allergic rhinitis and upper respiratory congestion.
Approved indications
- Allergic rhinitis with nasal congestion
- Urticaria and pruritus associated with allergies
- Upper respiratory allergy symptoms
Common side effects
- Drowsiness/sedation
- Dry mouth
- Nervousness/insomnia
- Tachycardia
- Headache
- Dizziness
Key clinical trials
- Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (PHASE3)
- Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: